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The Privilege of Induction Avoidance
and Calcineurin Inhibitors Withdrawal in
2 Haplotype HLA Matched White Kidney
Transplantation
Zaid Brifkani, MD,1 Daniel C. Brennan, MD,1 Krista L. Lentine, MD, PhD,2,3 Timothy A. Horwedel,4
Andrew F. Malone,1 Rowena Delos Santos, MD,1 Thin Thin Maw, MD,1 and Tarek Alhamad, MD, MS1,5
Background.White recipients of 2-haplotype HLA-matched living kidney transplants are perceived to be of low immunologic
risk. Little is known about the safety of induction avoidance and calcineurin inhibitor withdrawal in these patients.Methods.We
reviewed our experience at a single center and compared it to Organ Procurement and Transplantation Network (OPTN) registry
data and only included 2-haplotype HLA-matched white living kidney transplants recipients between 2000 and 2013. Results.
There were 56 recipients in a single center (where no induction was given) and 2976 recipients in the OPTN. Among the OPTN
recipients, 1285 received no induction, 903 basiliximab, 608 thymoglobulin, and 180 alemtuzumab. First-year acute rejection rates
were similar after induction-free transplantation among the center and induced groups nationally. Compared with induction-free
transplantation in the national data, there was no decrease in graft failure risk over 13 yearswith use of basiliximab (adjusted hazard
ratio [aHR], 0.86; confidence interval [CI], 0.68-1.08), Thymoglobulin (aHR, 0.92; CI, 0.7-1.21) or alemtuzumab (aHR, 1.18; CI,
0.72-1.93). Among induction-free recipients at the center, calcineurin inhibitor withdrawal at 1 year (n = 27) did not significantly im-
pact graft failure risk (HR,1.62; CI, 0.38-6.89).Conclusions. This study may serve as a foundation for further studies to provide
personalized, tailored, immunosuppression for this very low-risk population of kidney transplant patients.
(Transplantation Direct 2017;3: e133; doi: 10.1097/TXD.0000000000000645. Published online 8 February, 2017.)
H igh-risk versus low-risk kidney transplantation hasbeen defined epidemiologically and immunologically.
Epidemiologic high risks include African Americans and adoles-
cents.1,2 Immunologic risks include high panel-reactive antibody
(PRA) levels, ABO incompatibility, as well as HLA incom-
patibility.3-7 The few scenarios with very low immunologic
risk include transplantation between identical twins and be-
tween 2 haplotype HLA-matched siblings.8 The outcome ad-
vantages of 2-haplotypeHLA-matched living transplantation
include lower rejection rates and better overall patient and
graft survival compared with transplantation with greater
degrees of HLA mismatches.9-12
Currently, most immunosuppression protocols include anti-
body induction with calcineurin inhibitor (CNI) maintenance
regimens.13 The immunologic privilege of the 2-haplotype
living related transplant would seemingly allow for less over-
all immunosuppression. There are, however, few published
studies investigating the use and the type of induction, and
the intensity of maintenance therapy including withdrawal
of the CNI in 2-haplotype-matched living related transplants.
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Historically, African American recipients of 2-haplotype
living related transplants have higher rates and earlier onset
of rejections compared to their white counterparts. An analy-
sis of Organ Procurement and Transplantation Network
(OPTN) data of 2-haplotype HLAmatched living related kid-
ney transplants between 1984 and 1992 reported higher inci-
dences of acute rejection and poorer long-term graft survival
in black compared with white recipients.14 Because of the im-
munologic privilege afforded by a high-degreeHLA-matching,
it has been our center's policy that white, 2-haplotypematched
living related kidney transplant recipients do not receive induc-
tion and undergo CNI withdrawal within 6 to 12 months af-
ter transplantation. The aim of this study was to examine
center-specific and OPTN data to assess the safety and effi-
cacy of such practice in local and national experience.
METHODS
This study was approved by the institutional review board
of Washington University in St. Louis. Two-haplotype HLA
matched white kidney transplantation was defined as
white living donors matched with HLA A, B, C, DR,
DQ, and DP antigens by intermediate resolution DNA
typing by a Luminex Flow Analyzer with white sibling re-
cipients. None of these patients were from identical twins.
In the OPTN database, 2 haplotype was captured using
“HAPLO_TY_MATCH_DON” variable. These patients
were identified from January 2000 and December 2013 in
our center, “the center,” as well as those documented in
the OPTN database. The center patients who fell in this cat-
egory underwent transplantation without induction (center-
no-induction). In the OPTNdata, white 2-haplotypematched
siblings were analyzed according to induction: basiliximab,
thymoglobulin, alemtuzumab, or no induction (OPTN-
no-induction). Donor and recipient demographic and clinical
factors are summarized in Table 1. Peak PRAwas the highest
reported value before transplantation.
The center protocol calls for CNI withdrawal within the
first year; however, not all were withdrawn from the CNI
by 1 year. Thus, the center patients (n = 56) were divided ac-
cording to CNI status at 1 year into CNI continuation and
CNI withdrawal (Figure 1). All patients were on prednisone
5 mg daily as maintenance. None was in a prednisone avoid-
ance protocol. Twenty-seven patients achieved CNI with-
drawal by 1 year and were compared with 29 patients who
continued to be on CNI by year 1. Underlying reasons for
CNI continuation were: 4 with previous transplants, 3 with
antimetabolite discontinuation due to infections and ma-
lignancies, 3 with high risk of primary glomerulonephritis
recurrence, 1 with known history of poor medication ad-
herence, 1 with rejection within the first year, and 17 with
protocol deviation or preference of an outside provider for
CNI continuation. Of these 17 patients, 11 subsequently had
CNI withdrawal within the second and third year after trans-
plantation. Because of the small sample size and similar char-
acteristics, patients who continued CNI after the first year
were categorized in 1 group. Because of the limitations of
the data registry, patients could not be accurately categorized
according to CNI continuation in the national OPTN sample.
Graft Failure and Death
Graft and patient survival in the center-no-induction
group were compared with survival outcomes in the
induction groups in the OPTN. We also compared survival
outcomes between the OPTN-no-induction and the induc-
tion groups. Kidney allograft survival was defined as time
from initial transplant to retransplantation, initiation of dial-
ysis or recipient death. Thus, patient death was included as
allograft loss regardless of the functional status of the kidney
allograft at the time of death. Patient survival was considered
from time of transplant to patient death. Survival times were
censored at the study end on October 31, 2014.
Secondary Outcomes
Acute rejection within the first year of transplant was ex-
amined in the center group and compared with the OPTN in-
duction groups. Other secondary outcomes were assessed in
the form of infections and malignancies. Infections included
cytomegalovirus (CMV) and BK, whereas malignancies in-
cluded melanoma and posttransplant lymphoproliferative
disorder (PTLD).
Because OPTN data do not record CMVor BK viral infec-
tions unless reported as a cause of graft loss, we compared
the rates of CMV and BK infections between the center-
no-induction patients to all live donor kidney transplant
recipients at the center who received induction, mostly
thymoglobulin, during the same period as an internal con-
trol. CMV viremia was documented from quantitative
DNA analysis using the polymerase chain reaction assays.
BK was reported as either BK viremia or from evidence of
BK nephropathy on kidney allograft biopsy.
Formalignancies,we extracted rates ofmelanomaandPTLD
in the center-no-induction group and compared the results to
national recipients managed with and without induction.
Statistical Analysis
Recipient characteristics were described using proportions
for categorical variables, andmeanswith standard deviations
for continuous variables. Recipient and donor factors were
compared among the groups using aχ2 or Fisher test for cat-
egorical variables and analysis of variance test or Kruskal
Wallis tests for continuous variables, depending on the distri-
bution of the variable.
Allograft and recipient survival were assessed using the
Kaplan-Meier survival analysis, and P values were calculated
using the log-rank test. Multivariate analysis using the Cox
model was used to calculate the hazard ratio during the fol-
low up period for allograft failure and recipient death. In
the OPTN, the associations between the use and the type of
induction and kidney allograft and recipient survival were
assessed after adjusting for donor and recipient age, sex,
body mass index (BMI), hypertension (HTN), and other
recipient-specific variables, such as causes of ESRD, dialysis
before transplantation, PRA, and delayed graft function
(DGF) as listed in Table 1. Given the small available sample
for the center comparison, the multivariate model of center-
no-induction versus OPTN induction groups was adjusted
for a more limited set of baseline factors as follows: recipient
and donor age and recipient sex. Statistical analyses were per-
formed using SAS statistical software (version 9.4, Cary,NC).
RESULTS
Between January 2000 and December 2013, a total of 531
living-related kidney transplants were performed at the cen-
ter. Of these, 56 were performed between white 2-haplotype






































































































































































































































































































































































































































































































































































































































































© 2017 Wolters Kluwer Brifkani et al 3
matched siblings without induction (center-no-induction).
During the same period, 2976 patients were captured in the
OPTN that matched the criteria of white recipients of
2-haplotype matched live donor transplants. Of these, 1285
(43%) received no induction (OPTN-no-induction), 903
(30%) basiliximab, 608 (20%) thymoglobulin, and 180 (6 %)
alemtuzumab (Figure 1).
Demographics
Baseline demographic comparisons are shown in Table 1.
Donor and recipient characteristics of gender, age, and BMI
were similar between transplants at the center and national
experience in the OPTN. Baseline characteristics were also
similar across OPTN groups classified by induction, with
the exception that donors for the OPTN-no-induction trans-
plants were slightly younger than donors in the 3 OPTN in-
duction groups (P = 0.03). Recipient comorbidities, such as
peripheral vascular disease, chronic obstructive pulmonary
disease, and diabetes mellitus were similar between the
center-no-induction group and the OPTN induction groups
(P = 0.25, P = 0.14, and P = 0.24, respectively) and between
the OPTN-no-induction groups and the OPTN induction
groups (P = 0.19, P = 0.16, and P = 0.16, respectively). The
patients in the center-no-inductiongroupweremore likely tohave
HTN (P <0.01), cerebrovascular disease (CVD), (P <0.01),
and be on dialysis before transplantation (P = 0.03) than re-
cipients in the OPTN induction groups. Thirty-six percent of
patients in the center-no-induction group underwent pre-
emptive transplants, which was lower compared with the
OPTN-no-induction (42%), OPTN-basiliximab (39%), OPTN-
thymoglobulin (43%), andOPTN-alemtuzumab (50%)groups.
There were no episodes of DGF in the center-no-induction
group, which was not significantly different compared with
the OPTN induction groups (3% basiliximab, 3% thymo-
globulin, and 3% alemtuzumab; P = 0.61). A similar rate of
DGF was noted in the OPTN-no-induction group (2%,
P = 0.68). Other descriptive analyses are reported in Table 1.
Graft and Patient Survival: OPTN-No-Induction
vs OPTN Induction Groups
Graft and patient survival in the OPTN groups were simi-
lar regardless of induction use or type. The 1-, 5-, and 10-year
graft survival were as follows: no-induction (97%, 89%,
73%), basiliximab (98%, 90%, 77%), thymoglobulin (98%,
91%, 73%), and alemtuzumab (97%, 91%, 56%) (P = 0.49)
(Figure 2A). The 1-, 5-, and 10-year patient survival were:
no-induction (99%, 93%, 82%), basiliximab (99%, 94%,
86%), thymoglobulin (99%, 95%, 78%), and alemtuzumab
(99%, 95%, 86%) (P = 0.49) (Figure 2B).
After multivariate adjustment for recipient, donor and
transplant factors, graft failure risk was not significantly re-
duced with the use of induction with basiliximab (adjusted
hazard ratio [aHR], 0.86; confidence interval [CI], 0.68-
1.08; P = 0.19), thymoglobulin (aHR, 0.92; CI, 0.70-1.21;
P = 0.55), or alemtuzumab (aHR, 1.18; CI, 0.72-1.93;
P = 0.51) compared with OPTN-no-induction. There was
also no added patient benefit on mortality risk with
basiliximab (aHR, 0.88; CI, 0.65-1.18; P = 0.38), thymo-
globulin (aHR, 1.04; CI, 0.74-1.47; P = 0.82), alemtuzumab
(aHR, 1.02; CI, 0.53-1.98; P = 0.95) (Table 2). Other corre-
lates of graft failure and death are as listed in Table S1, SDC
(http://links.lww.com/PRSGO/A374).
FIGURE 1. Patient distribution stratified in OPTN by induction and in the center by CNI withdrawal.
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Graft and Patient Survival: Center-no-induction
vs OPTN Induction Groups
Kaplan-Meier estimates of graft and patient survival were
equivalent between the center-no-induction and the OPTN
induction groups. The 1-, 5-, and 10-year allograft survival
were as follows: OPTN-basiliximab (98%, 90%, 77%), OPTN-
thymoglobulin (98%, 91%, 73%), OPTN-alemtuzumab (97%,
91%, 56%), and center-no-induction (100%, 90%, 90%)
(P = 0.22) (Figure 3A). Patient survival at 1-, 5-, and 10-year
was also similar between the groups (P = 0.13) (Figure 3B).
Compared with the center-no-induction group, no im-
provement in graft survival was noted with basiliximab
(HR, 1.63; CI, 0.78-3.4; P = 0.19), thymoglobulin (HR,
1.78; CI, 0.85-3.77; P = 0.13), or alemtuzumab (HR, 2.03;
CI, 0.87-4.77; P = 0.1) induction after adjustment including
recipient age and sex and donor age. In addition, there was
no improvement in patient survival with the use of basiliximab
(HR, 2.13; CI, 0.65-6.97; P = 0.19), thymoglobulin (HR,
2.8; CI, 0.85-9.25; P = 0.09), or alemtuzumab (HR, 2.44;
CI, 0.65-9.22; P = 0.21) in the national experience compared
with center-non-induction (Table 2).
CNI Withdrawal
The kidney graft survival in the center-CNI-withdrawal
group at 1, 5, and 10 years was 100%, 89%, and 89%, re-
spectively, and similar to graft survival in the CNI continua-
tion group (100%, 92%, and 92%, respectively, P = 0.51)
(Figure 4A).
Patient survival in the CNI withdrawal group was 100%
at 1, 5, and 10 years and was statistically similar to survival
in the CNI continuation group (100%, 96%, and 96%, re-
spectively, P = 0.64) (Figure 4B).
FIGURE 2. Graft and patient survival in the OPTN-no-induction group compared to OPTN induction groups. A, Graft survival. B, Patient
survival.
TABLE 2.
Adjusted association of induction use and graft failure and patient death
OPTN-no-induction vs OPTN induction groups: adjusted association of induction use
Graft failure Patient death
Induction HR (95% CI) P HR (95% CI) P
OPTN no-induction Reference Reference
OPTN basiliximab 0.86 (0.68-1.08) 0.19 0.88 (0.65-1.18) 0.38
OPTN thymoglobulin 0.92 (0.70-1.21) 0.55 1.04 (0.74-1.47) 0.82
OPTN alemtuzumab 1.18 (0.72-1.93) 0.51 1.02 (0.53-1.98) 0.95
Center-no-induction vs OPTN Induction Groups: Adjusted Association of Induction Use
Graft failure Patient death
Induction HR (95% CI) P HR (95% CI) P
Center-no-induction Reference Reference
OPTN basiliximab 1.63 (0.78-3.4) 0.19 2.13 (0.65-6.97) 0.19
OPTN thymoglobulin 1.78 (0.85-3.77) 0.13 2.8 (0.85-9.25) 0.09
OPNT alemtuzumab 2.03 (0.87-4.77) 0.1 2.44 (0.65-9.22) 0.21
CVD, cardiovascular disease; GN, glomerulonephritis.
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Unadjusted Cox analysis showed that CNI withdrawal at
1 year was not associated with increased risk for graft failure
(HR, 1.62; CI, 0.38-6.89; P = 0.52) or patient death (HR,
0.56;CI, 0.05-6.31;P=0.64) comparedwithCNI continuation.
Secondary Outcomes: Rejection, Malignancy,
and Infection
Within 1 year of transplantation, there were 2 patients af-
fected by acute rejection in the center-no-induction group
(4%), similar to the rejection rate in the OPTN induction
groups (4% basiliximab, 3% thymoglobulin, and 1%
alemtuzumab; P = 0.19). Similarly, there was no difference
in the rejection rate between the OPTN-no-induction group
(3%) and the OPTN induction groups (P = 0.19).
There were no episodes of PTLD in the center-no-induction
group, which was not significantly different compared with
the OPTN induction groups (1% in each of basiliximab,
thymoglobulin, and alemtuzumab groups, P = 0.85). The
OPTN-no-induction group had a similar rate of PTLD
(1%, P = 0.89).
Similarly, there were no melanoma cases in the center-
no-induction group, and no difference in the melanoma
rate compared with the OPTN induction groups (1% for
basiliximab and thymoglobulin, and 0% alemtuzumab, P =
0.65). The OPTN-no-induction group had a similar rate of
melanoma (1%, P = 0.74).
The center-no-induction recipients had lower rates of BK
viremia compared to all live donor kidney transplant recipi-
ents who received induction at the center (7% vs 17%,
P = 0.046). However, the rates of CMV viremia were not dif-
ferent (8% vs 5%, P 0.62).
GN Recurrence
OPTN queries information on recurrent disease only as
cause of graft failure. We examined the subjects with ESRD
secondary to GN (n = 944) and identified 66 cases with allo-
graft failure. Of these, 35% (n = 23) had graft failure
FIGURE 3. Graft and patient survival in the center-no-induction group compared to the OPTN Induction groups. A, Graft survival. B, Patient
survival.
FIGURE 4. Graft and patient survival in the Center-no-induction group stratified by CNI withdrawal at 1 year post-kidney transplantation.
A, Graft survival. B, Patient survival.
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attributed as due to recurrent disease. Considered by regi-
men, the proportion of graft losses in patients with primary
GN attributed to recurrent disease was as follows, no-
induction, 26% (10 of 38); basiliximab, 50% (6 of 12);
thymoglobulin 54% (6 of 11); and alemtuzumab 20% (1 of
5) (P = 0.4). In our center, no graft failure was attributed to
recurrent GN. We do not do protocol biopsies, but among
the 21 patients with ESRD secondary to GN, 5 had a kidney
biopsy for a cause and only 1 had recurrent GN “FSGS
10 years after transplant,” but did not have a graft failure.
DISCUSSION
Overall, acute rejection rates have fallen and renal graft
outcomes have significantly improved over the past 15 years
with the introduction of antibody induction therapy and
CNIs.15-17 However, such potent immunosuppression may
increase the risk of malignancies, infections, and nephro-
toxicity.18-21
Tailored reduction of immunosuppression in low immu-
nologic risk patients may provide adequate protection
against acute rejection while reducing the risks of immuno-
suppression-related toxicities. However, in the transplant
community, there is still no consensus regarding the use or
the type of induction therapy that is needed in 2-haplotype
HLA matched white kidney transplant recipients. We
found wide variation in the use and type of induction
among these patients at a national level, with 30% receiving
basiliximab, 20% thymoglobulin, 6 % alemtuzumab, and
43% no induction.
The published literature on induction avoidance in these
patients is limited. One case series of 6 recipients of 2 haplo-
type matched living kidney transplants in Spain managed
with induction avoidance and CNI withdrawal within 3 to
12 months followed by mycophenolate maintenance showed
excellent outcomes, with only 1 episode of rejection over
10 years of follow up.22 The single rejection event was attrib-
uted to medication nonadherence.22 Glomerular filtration
rates were 54, 60, and 62 mL/min per 1.73 m2 at 3 months,
12 months, and last follow-up, respectively, in that study.22
Our study reports the largest experience of induction avoid-
ance in a single center, with equivalent outcomes of graft sur-
vival observed compared with different induction groups in
national experience and no increase in the rate of rejection
within the first year (2 patients of 56).
A prospective study of twenty 2-haplotype matched living
kidney transplant recipients assessed the 1-year outcomes
with antibody induction, steroid avoidance, and subsequent
withdrawal of tacrolimus and (or) sirolimus. There were no
significant acute rejection episodes observed over the
follow-up period and no statistically significant changes in
creatinine at 6, 12, and 24 months.23 A smaller study evalu-
ated 7 patients managed with mycophenolate maintenance
monotherapy after antibody induction and subsequent with-
drawal of CNIs.24 There were no episodes of rejection and se-
rum creatinine levels remained relatively unchanged during
the follow up period of 5 to 50 months.24 Another study
from the University of Minnesota reported experience with
2-haplotype HLA matched white living kidney transplant
recipients before 1984 (antilymphocyte globulin induction
and azathioprine-prednisone maintenance), 1984 to 1999
(Minnesota antilymphocyte globulin induction and CNI-
mycophenolate-prednisone maintenance), and 1999 to
2011 (thymoglobulin induction and CNI mycophenolate
maintenance) with n = 114, 262, and 77, respectively. There
was no difference in patient and graft survival between those
who did receive CNIs, with a trend toward higher rates of
chronic allograft nephropathy in CNI-exposed patients,
leading to the conclusion that CNI maintenance was not
warranted in this patient population.25 Our study confirms
these earlier findings by showing that CNIs can be with-
drawn in white recipients of 2-haplotype matched living re-
lated kidneys, but extends these findings by further showing
that this privileged group of patients do not require induction
therapy. This is an important observation with implications
for the immunosuppressive management and overall costs
of care for these patients.
Despite the relatively small numbers of CNI withdrawal
and CNI continuation groups, the 100% patient survival at
10 years in the CNI withdrawal arm supports the safety of in-
duction avoidance combined with CNI withdrawal at 1 year
for long-term survival in 2-haplotype HLA matched recipi-
ents. Notably, graft and patient survival with induction
avoidance were excellent in patients managed with either
CNI withdrawal or continuation, and further study in larger
samples is needed to determine if avoiding nephrotoxic
agents may provide additional benefits in these low immuno-
logic risk patients.
Our study has several limitations. First, it was not a con-
trolled prospective study, with all the limitations that come
with a retrospective study. Second, patients could not be ac-
curately categorized according to CNI continuation at the
OPTN level. Therefore, CNI withdrawal was examined only
at the single-center level. For secondary outcomes, there were
no detailed data on BK or CMVinfection available at OPTN;
therefore, we used a different control group of living donors
to study the effects of induction on these outcomes. Another
limitation, melanoma and PTLD might be underreported to
the OPTN, and the small number of events limits the power
for this comparison.
Our study also has unique strengths. We describe the
largest single-center experience of induction avoidance in
white recipients of 2-haplotype HLA-matched living re-
lated kidney transplants. Furthermore, we compared our
experience to a large pool of patients with induction cap-
tured in the national OPTN registry and also compared
the OPTN-no-induction group to the OPTN induction
groups, which adds more strength to the conclusions of
the study than if the comparison was done within the center
only. Another strength is the 13-year duration of follow-up,
which was adequate to see meaningful changes in graft and
patient survival.
In summary, long-term single center and national data in-
dicate excellent graft and patient outcomes in 2 haplotype-
matched white kidney transplant recipients managed with
induction avoidance and CNI withdrawal within the first
year of transplantation. This study can serve as a foundation
to provide personalized, tailored, immunosuppression for
this very low-risk population of kidney transplant patients.
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